AVITA Medical Inc (NASDAQ: RCEL) Announces Clinical Milestone
VALENCIA, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leader in therapeutic acute wound care, has announced the publication of its first clinical study evaluating Cohealyx™, a collagen-based dermal matrix. This significant advancement was published in the Journal of Surgery (Akpunonu et al., 2025).
The study highlights that Cohealyx demonstrated a remarkable improvement in wound bed vascularization and autograft readiness, achieving readiness in just 5 to 10 days, compared to the traditional two to four weeks required by conventional dermal matrices.
Clinical Case Series Findings
Conducted at The Ohio State University Wexner Medical Center, the case series involved two patients suffering from complex, full-thickness hand wounds. One patient exhibited a well-vascularized wound bed by day 5, allowing for autografting by day 7. The second patient achieved robust re-vascularization by day 10, proceeding to autografting on day 13. Both patients experienced excellent outcomes in skin graft take and functional recovery.
These outcomes indicate that Cohealyx may significantly enhance the speed of wound healing, leading to earlier definitive closure and, in turn, reducing the overall patient burden and associated complication risks.
CEO's Perspective
“This publication offers compelling validation of our preclinical findings, positioning Cohealyx as a major leap forward in wound management,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “Achieving autograft readiness in days rather than weeks is a breakthrough that can greatly improve clinical outcomes and elevate care standards for complex wounds.”
About Cohealyx™
Cohealyx is bioengineered with proprietary TetraPure™ Technology, incorporating crosslinked, purified collagen types I and III to support optimal cellular migration, rapid revascularization, and effective integration within the wound bed. Previous preclinical studies indicated readiness as early as day 7, and this recent publication marks the first clinical validation of those findings.
The complete study, titled “A Bovine Dermal Collagen Matrix (BDCM) Advances Readiness to Autografting: A Case Series,” can be accessed online at Gavin Publishers.
About AVITA Medical
AVITA Medical® is dedicated to providing transformative solutions in acute wound care. Our cutting-edge technologies, including the RECELL System®, are designed to optimize wound healing and accelerate patient recovery. The RECELL System harnesses a patient’s own skin to create Spray-On Skin™ Cells, enhancing clinical outcomes at the point of care. In the U.S., AVITA Medical holds exclusive rights to manufacture and distribute PermeaDerm® and Cohealyx™.
For more information, visit AVITA Medical or Inside Ticker.